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Abstract 
 
Acute eosinophilic myocarditis is a relatively rare disorder with serious morbidity 
and mortality. Due to its infrequency, standardized management guidelines are 
wanting. We present a case of acute, necrotizing eosinophilic myocarditis requiring 
several levels of critical care. We reviewed similar cases reported in the literature 
to highlight common clinical features, describe natural disease course and 
associated complications, and review varying approaches to medical therapy. 
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Introduction 
 
Acute necrotizing eosinophilic myocarditis is a rare and often fatal condition that 
can manifest as severely decompensated heart failure with biopsy revealing 
marked eosinophilic infiltration. We present a case of a 40-year-old male 
presenting with cardiogenic shock who transiently required veno-arterial 
extracorporeal membrane oxygenation while the diagnosis of acute necrotizing 
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eosinophilic myocarditis was made and treatment with immunosuppressive 
therapy was started.  
 
Case Presentation 
 
A 40-year-old African American male presented to his primary care physician with 
three days of subjective fevers, exertional dyspnea, and a non-productive cough. 
Past medical history was notable for gout managed with intermittent diclofenac. He 
had no reported allergies. Because of hypoxia on room air, he was referred to a 
local emergency room where chest x-ray demonstrated bilateral opacifications and 
he was admitted for treatment of community-acquired pneumonia. On the night of 
admission, respiratory failure ensued requiring mechanical ventilation. Subsequent 
electrocardiogram (ECG) performed showed concerns for anterior ST-elevation 
myocardial infarction (Figure 1). Initial troponin-I was 29 ng/mL. He was urgently 
taken to the cardiac catheterization lab but had no evidence of flow-limiting 
coronary artery disease. The patient’s clinical course continued to deteriorate 
necessitating intubation, empiric antibiotics, use of vasopressors and inotropes, 
and eventual placement of an intra-aortic balloon pump (IABP). Given the 
complexity of his medical illness, the patient was transferred to our institution for 
resumption of care. On the night of transfer, the patient experienced a five-minute 
episode of pulseless electrical activity arrest, which devolved into monomorphic 
ventricular tachycardia (VT) with pulse requiring defibrillation to restore normal 
sinus rhythm. Subsequent labs were remarkable for a white blood cell count of 19 
K/uL (peripheral eosinophils within normal limits), BUN of 60 mg/dL, creatinine of 
3.2 mg/dL, aspartate aminotransferase of 969 U/L, alanine aminotransferase of 
723 U/L, serum lactate of 2.8 mmol/L, and N-terminal pro b-type natriuretic peptide 
level of 42,000 pg/mL. 
 
 
 
Figure 1. Electrocardiogram demonstrating sinus tachycardia and ST elevation in 
the anterior and anterolateral precordial leads suggestive of acute infarction 
 
On day two, the patient’s oxygen requirements continued to increase, ultimately 
necessitating maximal ventilator support. Transthoracic echocardiogram showed 
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reduced left ventricular function with an estimated ejection fraction of 30-35%. 
Aggressive diuresis over the next 24 hours led to successful removal of the IABP 
and weaning of dobutamine. On the fourth day of hospitalization, the patient’s 
worsening clinical condition ultimately required veno-arterial extracorporeal 
membrane oxygenation (ECMO). A Maquet RotoFlow ECMO circuit was utilized 
with 17-French arterial and 25-French venous cannulation.  Initial flows were set at 
5.3 liters per minute.  Concomitant right-heart catheterization with endomyocardial 
biopsy was performed. On the night the patient was placed on ECMO, he 
developed persistent ventricular tachycardia treated with multiple defibrillations 
(thirty over a twelve-hour period), amiodarone pharmacotherapy, and 
transcutaneous pacing. Despite his electrical instability, the patient was maintained 
successfully on ECMO. 
 
Endomyocardial biopsy results returned the following day revealing inflammatory 
infiltrates with mixed T and B cell lymphocytes (predominantly of T-cell population) 
and eosinophils comprising 60-70% of the myocardial tissue (Figure 2).  
 
 
 
Figure 2.  Endomyocardial biopsy findings  
A. Hematoxylin and eosin (H&E), 200x: increased interstitial inflammatory infiltrate 
(black arrow) with increased eosinophils (red arrow). 
B. H&E, 400x demonstrating degranulated eosinophils (red arrow) and myocyte 
necrosis (white arrow) 
C. CD-3 immunohistochemical stain, 200x highlights T-cell lymphocytes 
D. CD-20 immunohistochemical stain, 200x marks B-cell lymphocytes 
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Overt myocyte necrosis was noted in roughly 20% of the tissue specimens. The 
patient was started on immunosuppressive therapy with high-dose steroids along 
with azathioprine. Over the course of his hospitalization, prednisone dosing was 
gradually weaned.  
 
Transthoracic echocardiography was performed on multiple occasions throughout 
the patient’s hospital course. Just prior to initiation of high-dose steroid therapy, his 
left ventricular ejection fraction (LVEF) was estimated at 5% with spontaneous 
echo contrast in the left ventricular (LV) cavity and absent aortic valve opening. 
After initiating steroid therapy, LV function quickly improved. With appropriate 
medical therapy, ventilator support was removed on day 11 and ECMO was 
discontinued on day 12 of hospitalization. Subsequent ECGs demonstrated normal 
sinus rhythm with poor R-wave progression in the anterolateral precordial leads. 
 
Several complications occurred over the patient’s hospital course. Despite 
adequate diuresis, blood urea nitrogen levels rose well above 200 mg/dL with 
resultant epistaxis and ECMO insertion site bleeding from presumed platelet 
dysfunction. The patient required multiple transfusions along with continuous renal 
replacement therapy for filtration of toxins. Kidney function recovered prior to 
discharge. Furthermore, the patient’s white blood cell count steadily decreased 
from 33 K/uL on day 17 to 1.3 K/uL on day 20 with an absolute neutrophil count of 
500 k/uL. Imuran was discontinued due to neutropenia and the leukopenia 
eventually resolved. Perhaps the most concerning complication was the 
development of a necrotizing pneumonia with several large cavitary areas resulting 
in a spontaneous pneumothorax. On day 42 of hospitalization, re-intubation was 
required along with chest tube placement. Bronchoalveolar lavage was positive for 
Candida albicans and therapy with fluconazole was started. Despite several 
complications, the patient continued to improve and recovered enough to be 
discharged to a rehabilitation facility on day 72 of hospitalization. 
 
Discussion 
 
Eosinophilic myocarditis is a rare condition characterized by myocardial 
inflammation with eosinophilic infiltration. The disease is most commonly seen in 
hypereosinophilic syndrome (defined as an absolute eosinophil count greater than 
1.5×109/L), with up to 60% of patients having myocardial involvement1. This form 
of eosinophilic myocarditis is commonly chronic, occurring in the presence of 
extra-cardiac symptoms with notable eosinophilia in peripheral blood. Established 
etiologic factors include hypersensitivity reactions to medications, helminths, 
vaccines (such as smallpox, meningococcal, and hepatitis B), hypereosinophilic 
syndrome, tropical endomyocardial fibrosis, transplant rejection, certain 
vasculitides such as Churg-Strauss, and some malignancies. Diclofenac exposure 
was suspected to be the culprit in our patient, though methyldopa, 
hydrochlorothiazide, ampicillin, furosemide, digoxin, tetracycline, aminophylline, 
phenytoin, benzodiazepines, and tricyclic antidepressants are more commonly 
recognized offending medications2. 
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Necrosis is an uncommon finding in the setting of eosinophilic myocarditis. 
Eosinophilic necrotizing myocarditis often has a fulminant course with many 
diagnoses made posthumously via autopsy1, 3. Prior autopsy series noted that only 
37 out of 69 autopsied hearts with eosinophilic myocarditis demonstrated a focus 
of necrosis. Though myocarditis was the reported cause of death in many of these 
patients, none demonstrated extensive necrosis by histology4. It is important to 
note that as many diagnoses are made post-humously, endomyocardial biopsy 
may miss areas of eosinophilic infiltration adding another wrinkle to the challenging 
diagnosis. This entity has a rapidly progressive course with profound 
hemodynamic compromise, often culminating in cardiogenic shock. A high index of 
suspicion is needed as death may occur days or weeks after the onset of 
symptoms, with or without extra-cardiac involvement3. Our patient presented to an 
outside facility and treated for community acquired pneumonia. The possibility of 
eosinophilic pneumonia could have been a subtle clue towards our diagnosis. 
Death may occur days or weeks after the onset of symptoms, with or without extra-
cardiac involvement3. It is notable that even among patients with fulminant 
myocarditis, most cases are lymphocytic. In the series of eight cases in a single 
institution, only one case of fulminant myocarditis was of eosinophilic (as opposed 
to lymphocytic) infiltration of the myocardium5. 
 
Due to the rarity of necrotizing eosinophilic myocarditis, evidence-based treatment 
guidelines are not available. In this case, once a diagnosis was confirmed via 
endomyocardial biopsy, a literature search was conducted for case reports of 
patients with similar presentation and pertinent features – including natural disease 
course and prognosis, well-described complications, optimal treatment, and most 
importantly, dose and duration of steroid therapy. 
 
Table 1 displays a series of cases of myocardial eosinophilic infiltration and 
extensive necrosis confirmed on pathology (biopsy or autopsy). Cases with mild 
focal necrosis were not included. A case in which myocarditis developed after 
withdrawal of steroids used for other conditions was excluded6. A case of 
myocarditis in a patient with a pre-existent severe cardiomyopathy with ejection 
fraction of 20% was also excluded7. 
 
Twenty case reports were included in our search and with our patient; we reviewed 
21 cases of fulminant, necrotizing, eosinophilic myocarditis. Out of 21 patients, 15 
survived and 6 died. This cannot serve as an estimate of prognosis because cases 
with more favorable outcomes were reported and published with higher frequency. 
We can presume, however, that the notion of necrotizing, eosinophilic myocarditis 
as a post-mortem diagnosis is largely untrue. Male and female patients were 
represented evenly (12 men and 9 women). Electrocardiogram findings were 
reported in 16 cases. Of these 16 ECGs, ST elevation was present in 11 cases 
(68.8%). Due to this finding, many patients underwent unnecessary coronary 
angiography, which was uniformly unremarkable as the ST elevation was related 
to the infiltrative process with resultant myocardial necrosis. Coronary angiography 
was understandably difficult to avoid during initial management of these patients 
given the concern for acute coronary syndrome. More importantly, six patients 
(37.5% of those with reported ECG findings) experienced sustained ventricular 
tachycardia or ventricular fibrillation, and, of these, two did not survive. The high 
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rate of fatal arrhythmias, which can be poorly responsive to conventional therapies 
such as defibrillation and antiarrhythmics, makes a case for the liberal use of 
mechanical circulatory support. Mechanical circulatory support seems to be the 
only treatment modality than can sustain a patient through a prolonged period of 
electrical instability. 
 
Elevated cardiac enzymes were present in each case where enzymes were 
collected, and therefore were not included in our table. The presence or absence 
of peripheral eosinophilia was mentioned in all but one case. Eosinophilia was 
present in 12 cases and absent in 8, including ours. Among the 15 survivors, 
peripheral eosinophilia was present in at least 8 patients (57.1%) with one case 
not reporting such a finding. Four (66.6%) of the deceased patients had peripheral 
eosinophilia. Although the sample size is undeniably small, it seems unlikely that 
peripheral eosinophilia has a major bearing on prognosis. There seems to be no 
relationship among peripheral eosinophil count, the extent of eosinophilic infiltrate, 
and clinical symptoms8. Echocardiogram invariably demonstrates profound left 
ventricular systolic dysfunction. Even when patients were admitted with normal or 
mildly impaired left ventricular function, it deteriorated within a matter of hours or 
days. Interestingly, thickening of the left ventricular wall, resembling hypertrophy, 
was noted in several cases and was likely related to eosinophilic infiltration. This 
feature, along with systolic dysfunction, can be reversible with successful 
treatment1. In some cases, thickening reached nearly 2 cm3. Spontaneous echo 
contrast was noted in the left ventricular cavity by one group of authors9 (as in our 
patient). Apical thrombus has also been reported10. Both findings are consistent 
with a low flow state. Cardiac imaging, predominantly echocardiography, was 
performed at random intervals at the discretion of the individual authors. We 
performed serial echocardiograms throughout our patient’s hospital course. From 
our experience, and from other reports, once the initial response to steroids was 
positive, near normal or normal ventricular function was restored within 21 days10-
12, regardless of the initial severity of left ventricular dysfunction. Due to difficult 
logistic reasons, a cardiac MRI was unable to be performed. Though often difficult 
to obtain in a critical care setting, it is possible that CMR features of eosinophilic 
myocarditis could help guide initiation of steroid therapy and consideration of this 
imaging modality is warranted. 
 
In terms of extra-cardiac complications, our patient developed severe renal 
dysfunction and required renal replacement therapy for several weeks. Within our 
case series, only one other patient was reported to have acute kidney injury and 
required continuous renal replacement therapy for several days12. Our patient was 
the only one to develop a cavitary necrotizing pneumonia requiring prolonged 
mechanical ventilation which may have been related to the dose and tapering of 
steroids. 
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Table 1 – Cases of Eosinophilic Myocarditis with Extensive Necrosis 
Author 
Age 
and 
Gender 
ECG findings 
Peri-
pheral 
eosino-
philia 
MCS Echocardiogram Findings Outcome Steroid Management 
Aggarval13 
46, 
male 
ST elevation No 
IABP for 
6 days 
Severe LV systolic dysfunction, 
thickening of ventricular walls. 
Normalization in 2 weeks. 
Survived 
Methylprednisolone 1 g/day IV for 2 days, 
then oral tapering dose 
Watanabe16 
55, 
male 
 No IABP 
LVEF of 23% with increased wall 
thickness. Improved to 44% in 3 
days. Normal in 2 weeks. 
Survived 
Methylprednisolone 1 g/day IV for 3 days, 
then prednisone 60 mg/day for 2 weeks 
Al Ali17 
50, 
male 
ST elevation in 
inferolateral 
leads 
Yes None LVEF 45%. Normal in 2 months Survived Prednisone 1 mg/kg/day PO 
Al Ali17 
26, 
male 
  None 
LVEF 20% with normal RV/LV 
size. Normal in 4 months 
Survived Prednisone 1 mg/kg/day PO 
Corradi15 
23, 
female 
Non-specific ST-
T wave changes 
Yes  LVEF 20% with LV dilatation Survived 
Methylprednisolone 1 g/day IV for 3 days, 
then prednisone 1 mg/kg/day PO with taper 
over 1 year 
Allen12 
48, 
female 
Diffuse ST 
elevations; 
sustained VT 
No 
ECMO 
for 5 
days 
Moderate-severe biventricular 
dysfunction, normal RV/LV 
sizes. Normalization in 5 days 
Survived 
Methylprednisolone 1 g/day IV for 3 days, 
then prednisone 1 mg/kg/day PO with taper 
over 6 weeks 
Cooper1 
47, 
female 
ST elevation V1-
V3; sustained 
VF/VT 
Yes 
BiVAD 
for 2 
weeks 
LVEF 25%. Improved to 45% in 
2 weeks 
Survived 
Methylprednisolone 10 mg/kg/day for 3 days, 
then prednisone 1 mg/kg PO daily, then 
decreased to 5 mg daily after 4 weeks 
Enriquez18 
65, 
male 
ST elevation V1-
V3 
Yes None 
LVEF 30-35%. Normalization in 
6 months 
Survived 
Methylprednisolone 0.5 g/day IV, then 
prednisone 1 mg/kg/day PO at tapering dose 
Thambidora
i9 
54, 
male 
ST elevation in 
anterolateral 
leads 
Yes None 
LVEF 30-35%, increased wall 
thickness, “smoke”. Slight 
improvement in 1 week. Normal 
at 6 months 
Survived 
Methylprednisolone 300 mg/day IV for 1 
week, then prednisone 60 mg/day PO for 1 
week, followed by oral taper over 6 months 
Galiuto10 
67, 
female 
ST elevation V2-
V6 
Yes None 
LVEF 35% with LV dilation and 
apical thrombus.  Improved to 
70% in 1 week 
Survived 
Prednisone 60 mg PO daily for 2 weeks 
followed by taper to 10 mg every other day 
before stopping at 2 months 
Getz19 
41, 
female 
ST elevation 
inferiorly and 
anteriorly 
No None 
Moderate LV dysfunction, 
increased wall thickness, dilated 
and hypertrophied RV with 
severe dysfunction. 
Survived 
Methylprednisolone 1 g/day IV for 3 days, 
then prednisone 60 mg/day PO 
Huntgeburth
20 
55, 
female 
ST abnormality 
in lateral leads 
Yes None 
LVEF 19% with LV dilatation. 
LVEF improved to 43% in 4 
months 
Survived 
Prednisolone 75 mg/day PO for 5 days 
tapered to 10 mg/day 
Khabbaz11 
19, 
female 
 Yes 
ECMO 
for 10 
days 
LVEF < 10%, RV/LV dilatation. 
Improvement in 6 days and 
normalization in 10 days 
Survived Steroids 
Kohout14 
37, 
male 
ST elevation in 
V1-V4 with VF 
No 
LVAD for 
1 month 
LVEF 10% with increased wall 
thickness and RV dilatation with 
hypokinesis. Normalization in 1 
month. 
Survived 
Methylprednisolone 1 g/day IV for 3 days, 
then prednisone PO tapering for an 
additional 3 days (60 mg/day, 40 mg/day, 
and 20 mg/day) 
Hyogo21 
41, 
male 
Right bundle 
branch block, 
posterior 
fascicular block, 
VT/VF 
Yes None 
LVEF 28% with increased wall 
thickness 
Died None 
Arsenovic4 
41, 
male 
 Yes   Died None 
Herzog3 
22, 
male 
Left bundle 
branch block, VF 
Yes  
Global systolic dysfunction by M-
mode and increased wall 
thickness 
Died None 
Herzog3 
47, 
male 
Right bundle 
branch block 
Yes   Died None 
Adamson22 
51, 
female 
ST elevation V1-
V4, VT 
No None 
LVEF 25% with increased wall 
thickness 
Died  
Fragkouli23 
66, 
female 
ST elevation V3-
V5 
No None 
LVEF 25% with mildly increased 
wall thickness 
Died None 
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It seems clear from the combined experience within our case review, that high-
dose steroids are a mandatory treatment for necrotizing eosinophilic myocarditis. 
There was no single case of survival in patients who did not receive high-dose 
steroids. Methylprednisolone or prednisone should be given as soon as the 
diagnosis is confirmed or even suspected. The variability of doses is reflected in 
Table 1. Methylprednisolone 1 g/day intravenously appears to be the most 
frequently used dose, although some authors gave lower doses. In the only case 
in which the authors opted to start with oral prednisone, the degree of left 
ventricular dysfunction was the mildest (EF of 35%)10. Of note, the Myocarditis 
Treatment Trial, demonstrated a lack of benefit of corticosteroids in acute 
myocarditis8. However, this is not applicable to our series of patients, as only those 
meeting the Dallas criteria (with lymphocytic as opposed to eosinophilic infiltration 
of myocardium) were included in the trial. 
 
Other steroid-sparing agents, such as azathioprine in our patient, were used in 
other cases13. It is unclear whether steroids are sufficient or if other agents can 
contribute to management success. Cooper et al added mycophenolate mofetil 
and then sirolimus when steroids were decreased to prednisone 5 mg/day1. 
Interestingly, this was the only case with partial recurrence of myocarditis. 
 
There does not seem to be any agreement regarding the rapidity of steroid 
tapering. Based on our collection of case reports, relapse is uncommon after initial 
progress is achieved. The only exception was a temporary decrease in ejection 
fraction (after initial complete recovery) to 40% months later1. There does not 
seem to be any agreement regarding the rapidity of steroid tapering. Based on our 
collection of case reports, relapse is uncommon after initial progress is achieved. 
The only exception was a temporary decrease in ejection fraction (after initial 
complete recovery) to 40% months later14. We were more cautious with our steroid 
taper and the necrotizing pneumonia our patient developed could be a 
consequence of this. On the other hand, Corradi et al tapered prednisone over one 
year15. Though there is a lack of randomized evidence, it seems that tapering 
steroids to complete discontinuation in two to four weeks is reasonable. 
 
Mechanical circulatory support in the form of intra-aortic balloon pump (3 cases) or 
extracorporeal membrane oxygenation (3 cases including ours), or ventricular 
assist devices (2 cases) was used in a total of 7 cases. A balloon pump was 
followed by a ventricular assist device in one case1. The time of support ranged 
from 3 days to one month. All patients, regardless of the type of mechanical 
support, ultimately survived. 
 
Conclusion 
 
Fulminant eosinophilic necrotizing myocarditis is a rare condition rapidly 
progressing to hemodynamic compromise including cardiogenic shock and cardiac 
arrest from sustained ventricular arrhythmias. It may have an excellent prognosis if 
aggressively treated in a timely manner with high doses of steroids and 
mechanical circulatory support if needed. The timely diagnosis by endomyocardial 
biopsy is critical. Empiric treatment while awaiting pathology results is justified. 
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Mechanical circulatory support should not be delayed, as it may be lifesaving, 
especially in the case of refractory ventricular tachycardia/fibrillation. Complete 
cardiac recovery can occur in a matter of days. Weaning of steroids can be done 
rapidly, within several weeks, to avoid steroid-related complications.  
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